BR0209269A - Terapia de combinação antiangiogênica para o tratamento de câncer - Google Patents
Terapia de combinação antiangiogênica para o tratamento de câncerInfo
- Publication number
- BR0209269A BR0209269A BR0209269-7A BR0209269A BR0209269A BR 0209269 A BR0209269 A BR 0209269A BR 0209269 A BR0209269 A BR 0209269A BR 0209269 A BR0209269 A BR 0209269A
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- cancer treatment
- antiangiogenic
- antiangiogenic combination
- inhibitory agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"TERAPIA DE COMBINAçãO ANTIANGIOGêNICA PARA O TRATAMENTO DE CâNCER". A presente invenção proporciona combinações de um agente inibidor de topoisomerase I de DNA e de um agente inibidor seletivo COX-2 para prevenir, tratar e/ou reduzir o risco de desenvolver um distúrbio neoplásico em um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/843,132 US20020103141A1 (en) | 1998-12-23 | 2001-04-25 | Antiangiogenic combination therapy for the treatment of cancer |
PCT/US2002/013219 WO2002085459A2 (en) | 2001-04-25 | 2002-04-25 | Antiangiogenic combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209269A true BR0209269A (pt) | 2004-06-22 |
Family
ID=25289143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209269-7A BR0209269A (pt) | 2001-04-25 | 2002-04-25 | Terapia de combinação antiangiogênica para o tratamento de câncer |
Country Status (15)
Country | Link |
---|---|
US (2) | US20020103141A1 (pt) |
EP (1) | EP1414526A2 (pt) |
JP (1) | JP2004529150A (pt) |
KR (1) | KR20040018364A (pt) |
CN (1) | CN1520324A (pt) |
BR (1) | BR0209269A (pt) |
CA (1) | CA2444219A1 (pt) |
CZ (1) | CZ20032783A3 (pt) |
EA (1) | EA200301104A1 (pt) |
IL (1) | IL158329A0 (pt) |
MX (1) | MXPA03009886A (pt) |
NO (1) | NO20034780L (pt) |
PL (1) | PL367198A1 (pt) |
WO (1) | WO2002085459A2 (pt) |
ZA (1) | ZA200402546B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
ATE282831T1 (de) * | 2001-12-04 | 2004-12-15 | Brahms Ag | Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente |
GB0208516D0 (en) * | 2002-04-15 | 2002-05-22 | Univ Liverpool | Chemotherapy |
WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
EP1575582A4 (en) * | 2002-11-06 | 2009-03-11 | Wyeth Corp | COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME |
US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US7332525B2 (en) | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
US20050187172A1 (en) * | 2003-12-23 | 2005-08-25 | Masferrer Jaime L. | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia |
WO2006011047A1 (en) * | 2004-07-23 | 2006-02-02 | Pharmacia & Upjohn Company Llc | Enantioselective method for separing substituted 2-trifluoromethyl-2h-chromene-3-carboxylic acid derivatives |
US7122700B2 (en) | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
SI1827437T1 (sl) * | 2004-12-15 | 2012-02-29 | Sigma Tau Ind Farmaceuti | Kombinacije terapevtskih sredstev za zdravljenje raka |
EP2056805B1 (en) * | 2006-08-16 | 2011-05-25 | Action Medicines, S.L. | Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases |
EP2245459A1 (en) | 2008-01-23 | 2010-11-03 | Herlev Hospital | Ykl-40 as a general marker for non-specific disease |
EP2338486A1 (en) * | 2009-12-18 | 2011-06-29 | Johannes Gutenberg-Universität Mainz | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
GB201000196D0 (en) * | 2010-01-07 | 2010-02-24 | Galvez Julian M | Novel combination |
US9125899B1 (en) * | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
JP6284541B2 (ja) * | 2012-11-28 | 2018-02-28 | ネクター セラピューティクス | 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 |
CN103012350B (zh) * | 2012-12-07 | 2015-02-04 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
TWI646091B (zh) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | 鹽類及晶形 |
CN110997008A (zh) * | 2017-06-12 | 2020-04-10 | 斯坦尼斯劳·R·布任斯基 | 用于治疗软脑膜疾病的方法 |
US11344521B2 (en) | 2017-06-12 | 2022-05-31 | Burzynski Research Institute, Inc. | Methods for the treatment of leptomeningeal disease |
EP3762368B1 (en) | 2018-03-08 | 2022-01-26 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2239429C2 (ru) * | 1996-10-15 | 2004-11-10 | Джи. Ди. Сирл Энд Ко. | Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
ATE266634T1 (de) * | 1998-04-10 | 2004-05-15 | Pfizer Prod Inc | Cyclobutyl-aryloxysulfonylamin- hydroxamsäurederivate |
PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) * | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US6294558B1 (en) * | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6277878B1 (en) * | 1998-09-07 | 2001-08-21 | Pfizer Inc | Substituted indole compounds as anti-inflammatory and analgesic agents |
US6114361A (en) * | 1998-11-05 | 2000-09-05 | Pfizer Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
JP2002533387A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法 |
DK1041072T3 (da) * | 1999-03-31 | 2003-11-10 | Pfizer Prod Inc | Dioxocyclopentylhydroxamsyrer |
MXPA00006605A (es) * | 1999-07-02 | 2004-12-09 | Pfizer | Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos. |
-
2001
- 2001-04-25 US US09/843,132 patent/US20020103141A1/en not_active Abandoned
-
2002
- 2002-04-25 PL PL02367198A patent/PL367198A1/xx not_active Application Discontinuation
- 2002-04-25 JP JP2002583032A patent/JP2004529150A/ja not_active Withdrawn
- 2002-04-25 EA EA200301104A patent/EA200301104A1/ru unknown
- 2002-04-25 BR BR0209269-7A patent/BR0209269A/pt not_active IP Right Cessation
- 2002-04-25 CZ CZ20032783A patent/CZ20032783A3/cs unknown
- 2002-04-25 CN CNA028126319A patent/CN1520324A/zh active Pending
- 2002-04-25 IL IL15832902A patent/IL158329A0/xx unknown
- 2002-04-25 CA CA002444219A patent/CA2444219A1/en not_active Abandoned
- 2002-04-25 KR KR10-2003-7014051A patent/KR20040018364A/ko not_active Application Discontinuation
- 2002-04-25 MX MXPA03009886A patent/MXPA03009886A/es not_active Application Discontinuation
- 2002-04-25 WO PCT/US2002/013219 patent/WO2002085459A2/en active Application Filing
- 2002-04-25 EP EP02731524A patent/EP1414526A2/en not_active Withdrawn
-
2003
- 2003-10-24 US US10/692,643 patent/US20040127539A1/en not_active Abandoned
- 2003-10-24 NO NO20034780A patent/NO20034780L/no not_active Application Discontinuation
-
2004
- 2004-03-31 ZA ZA200402546A patent/ZA200402546B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002085459A3 (en) | 2004-03-04 |
KR20040018364A (ko) | 2004-03-03 |
CN1520324A (zh) | 2004-08-11 |
CA2444219A1 (en) | 2002-10-31 |
NO20034780D0 (no) | 2003-10-24 |
MXPA03009886A (es) | 2004-11-22 |
NO20034780L (no) | 2003-12-12 |
US20020103141A1 (en) | 2002-08-01 |
ZA200402546B (en) | 2005-04-26 |
EA200301104A1 (ru) | 2004-06-24 |
WO2002085459A2 (en) | 2002-10-31 |
IL158329A0 (en) | 2004-05-12 |
JP2004529150A (ja) | 2004-09-24 |
PL367198A1 (en) | 2005-02-21 |
EP1414526A2 (en) | 2004-05-06 |
CZ20032783A3 (cs) | 2004-11-10 |
US20040127539A1 (en) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209269A (pt) | Terapia de combinação antiangiogênica para o tratamento de câncer | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
ATE430570T1 (de) | Synergistische kombinationstherapie zur krebsbehandlung | |
BR0211978A (pt) | Terapia de combinação para o tratamento de câncer | |
WO2004050026A3 (en) | Compositions and methods for treating prostate cancer | |
IL143805A0 (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
CZ2000531A3 (en) | Method of prevention or therapy of estrogen-dependent diseases and disorders | |
HUP0104688A2 (hu) | Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez | |
BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
WO2003049804A3 (en) | Treatment of genitourinary tract disorders | |
MX2022014180A (es) | Metodos, terapias y usos para tratar cancer. | |
BR0311146A (pt) | Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino | |
IS6576A (is) | Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini | |
DK1133296T3 (da) | Ny terapeutisk anvendelse af nicergolin | |
BR0317491A (pt) | Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia | |
MX2023003034A (es) | Metodos, terapias y usos para tratar el cancer. | |
BR0212446A (pt) | Uso de 4-piridilmetilftalazinas para tratamento de câncer | |
BR0111740A (pt) | Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação | |
WO2003079748A3 (en) | Potentiation of cancer therapies by znf217 inhibition | |
BR0308976A (pt) | Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia | |
MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. | |
PT1133297E (pt) | Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina | |
ES2170479T3 (es) | Agente viral terapeutico que detiene el desarrollo de tumores. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61P 35/00 (2006.01) |